Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Apiam Animal Health (AHX AU): Adamantem's A$0.87/Share Offer

Quiddity Advisors

Event-Driven

<ul>
<li>
<strong><a href="https://www.smartkarma.com/entities/apiam-animal-health-ltd" target="_blank" data-smartkarma-citation="entities:26109:1" rel="noopener">Apiam Animal Health (AHX AU)</a></strong>, Australia's largest rural and regional veterinary group, has announced a non-binding indicative Offer from PE outfit Adamantem Capital.  </li>
<li>
<strong>Adamantem is offering A$0.88/share</strong>, a 64.5% premium to last close. If terms are firmed, shareholders will also be afforded a partial scrip option into an unlisted bidco. </li>
<li>Adamantem has also entered into a call option for 19.9% of shares out at A$0.88/share. An independent board committee are assessing the approach. Due diligence not yet granted.</li>
</ul>



Apiam Animal Health (AHX AU), Australia's largest rural and regional veterinary group, has announced a non-binding indicative Offer from PE outfit Adamantem Capital.  

Adamantem is offering A$0.88/share, a 64.5% premium to last close. If terms are firmed, shareholders will also be afforded a partial scrip option into an unlisted bidco. 
Adamantem has also entered into a call option for 19.9% of shares out at A$0.88/share. An independent board committee are assessing the approach. Due diligence not yet granted.


Oneconnect Financial Technology (6638 HK)

Apiam Animal Health (AHX AU): Adamantem's NBIO